Literature DB >> 16439608

Newborn screening for hepatorenal tyrosinemia: Tandem mass spectrometric quantification of succinylacetone.

Johannes Sander1, Nils Janzen, Michael Peter, Stefanie Sander, Ulrike Steuerwald, Ute Holtkamp, Bernd Schwahn, Ertan Mayatepek, Friedrich K Trefz, Anibh M Das.   

Abstract

BACKGROUND: False-positive and false-negative results occur in current newborn-screening programs for hepatorenal tyrosinemia, which measure tyrosine concentrations in blood spots, sometimes in combination with other metabolites, including succinylacetone. We present our experience with a newly described method for succinylacetone quantification in routine newborn screening.
METHODS: Succinylacetone was extracted from blood spots that had already been extracted with absolute methanol for acylcarnitine and amino acid analysis. The solvent was acetonitrile-water (80:20 by volume) containing formic acid, hydrazine hydrate, and 100 nmol/L 5,7-dioxooctanoic acid as internal standard. Analysis was performed by tandem mass spectrometry in a separate run.
RESULTS: Of 61,344 samples, 99.6% had succinylacetone concentrations < or =5 micromol/L. With a cutoff of 10 micromol/L, no false-positive results were obtained. In 2 patients, the succinylacetone concentrations in the dried blood spots from the 36th and 56th hours of life were 152 and 271 micromol/L, respectively, and the tyrosine concentrations were 54 and 129 micromol/L. Hepatorenal tyrosinemia was subsequently confirmed in both patients. Retrospective analysis of the neonatal screening samples of 2 additional known patients revealed increased succinylacetone concentrations of 46 and 169 micromol/L, respectively.
CONCLUSIONS: Tandem mass spectrometric quantification directly from residual blood spots is a useful method for the early detection of hepatorenal tyrosinemia in newborn-screening programs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439608     DOI: 10.1373/clinchem.2005.059790

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  14 in total

1.  Newborn screening.

Authors:  James J Pitt
Journal:  Clin Biochem Rev       Date:  2010-05

2.  Application of a second-tier newborn screening assay for c5 isoforms.

Authors:  T Cloppenborg; N Janzen; Hj Wagner; U Steuerwald; M Peter; Am Das
Journal:  JIMD Rep       Date:  2013-11-06

3.  Newborn Screening for Tyrosinemia Type I: Further Evidence that Succinylacetone Determination on Blood Spot Is Essential.

Authors:  Giancarlo la Marca; Sabrina Malvagia; Elisabetta Pasquini; Catia Cavicchi; Amelia Morrone; Federica Ciani; Silvia Funghini; Fabio Villanelli; Enrico Zammarchi; Renzo Guerrini
Journal:  JIMD Rep       Date:  2011-06-22

4.  The national Austrian newborn screening program - eight years experience with mass spectrometry. past, present, and future goals.

Authors:  David C Kasper; Rene Ratschmann; Thomas F Metz; Thomas P Mechtler; Dorothea Möslinger; Vassiliki Konstantopoulou; Chike B Item; Arnold Pollak; Kurt R Herkner
Journal:  Wien Klin Wochenschr       Date:  2010-10-15       Impact factor: 1.704

5.  Development of Flow Injection Analysis Method for the Second-Tier Estimation of Succinylacetone in Dried Blood Spot of Newborn Screening.

Authors:  Bijo Varughese; Dnyanoba Madrewar; Sunil Kumar Polipalli; Seema Kapoor
Journal:  Indian J Clin Biochem       Date:  2021-01-06

6.  Performance of succinylacetone assays and their associated proficiency testing outcomes.

Authors:  B W Adam; E M Hall; N K Meredith; T H Lim; C A Haynes; V R De Jesus; W H Hannon
Journal:  Clin Biochem       Date:  2012-08-11       Impact factor: 3.281

7.  A mass spectrometric study for comparative analysis and evaluation of metabolite recovery from plasma by various solvent systems.

Authors:  Anwesha Dutta; Premalatha Shetty; Smitha Bhat; Yeshaswini Ramachandra; Shrinidhi Hegde
Journal:  J Biomol Tech       Date:  2012-12

8.  Significant increase of succinylacetone within the first 12 h of life in hereditary tyrosinemia type 1.

Authors:  Jan-Ulrich Schlump; Ertan Mayatepek; Ute Spiekerkoetter
Journal:  Eur J Pediatr       Date:  2009-10-08       Impact factor: 3.183

9.  Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007).

Authors:  D Matern; S Tortorelli; D Oglesbee; D Gavrilov; P Rinaldo
Journal:  J Inherit Metab Dis       Date:  2007-07-23       Impact factor: 4.982

10.  Incorporation of second-tier tests and secondary biomarkers to improve positive predictive value (PPV) rate in newborn metabolic screening program.

Authors:  Sarang Younesi; Bahareh Yazdani; Mohammad Mahdi Taheri Amin; Pourandokht Saadati; Soudabeh Jamali; Mohammad-Hossein Modarresi; Shahram Savad; Saloomeh Amidi; Homayoun Razavi; Soudeh Ghafouri-Fard
Journal:  J Clin Lab Anal       Date:  2022-05-02       Impact factor: 3.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.